Who
Corey Michael Watton
Director
Company insider
Files Form 4 as: Director, Zevra Therapeutics.
In numbers
- Trades disclosed
- 16
- Buys
- 5
- Sells
- 1
- Bought
- $12K
- Sold
- $277K
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 3 May 2023
- Last trade
- 10 Aug 2026
- Last filed
- 12 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Aug 2026filed 12 Aug 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | $61K12,300 at $4.97 | filing |
| 10 Aug 2026filed 12 Aug 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $138K12,300 at $11.25 | filing |
| 10 Aug 2026filed 12 Aug 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,300 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,300 at $0.00 | filing |
| 10 Aug 2026filed 12 Aug 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Code M | $61K12,300 at $4.97 | filing |
| 10 Aug 2026filed 12 Aug 2026 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Sold | $138K12,300 at $11.25 | filing |
| 4 Jun 2026filed 18 Jun 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 4 Jun 2026filed 18 Jun 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 29 May 2025filed 30 May 2025 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 28 Mar 2025filed 31 Mar 2025 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Bought | $2,352300 at $7.84 | filing |
| 11 Oct 2024filed 16 Oct 2024 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Bought | $3,960500 at $7.92 | filing |
| 13 May 2024filed 15 May 2024 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,200 at $0.00 | filing |
| 23 Jun 2023filed 26 Jun 2023 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Bought | $1,636275 at $5.95 | filing |
| 9 Jun 2023filed 13 Jun 2023 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Bought | $1,794325 at $5.52 | filing |
| 30 May 2023filed 31 May 2023 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Bought | $2,044400 at $5.11 | filing |
| 3 May 2023filed 8 May 2023 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —58,800 at $0.00 | filing |
News
Contrasting Clene (NASDAQ:CLNN) and Zevra Therapeutics (NASDAQ:ZVRA)ZVRA · tickerreport.com · 22 Oct 2026
0 headlines in the last 90 days name Corey Michael Watton; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.